Faded sexual interest can leave a woman upset
PT-141 clinical trials found slightly better desire and less distress.
Losing interest in sex bothered the women who took part. Two Phase 3 studies, the larger tests before approval, found small gains. A review questioned whether women noticed enough relief. That doubt deserves attention at your visit.
The short answer is slightly better desire than with placebo
Not wanting sex can upset a woman who once enjoyed sexual closeness. In the RECONNECT studies, PT-141 brought a slight rise in sexual interest [3]. Their lack of desire also upset the women a little less. Placebo, comparison shots with no drug, brought less improvement on both questions.
Questions asked the women about wanting sex and feeling upset when interest was low. Researchers judged those answers rather than simply counting how often women had sex. A later review doubted that women noticed enough benefit [9]. I'd ask your doctor what women gained in daily life alongside the unwanted effects.
PT-141 clinical trials compared desire during months of treatment
The RECONNECT studies tested 1,267 women in Phase 3, the larger testing before approval [3]. Women whose monthly periods hadn't ended received drug or placebo for 24 weeks. All had lost desire after previously having normal interest in sex. The loss distressed them regardless of the setting or partner.
Question 13 asked how upset women felt about lacking sexual interest [3]. The medicine brought slightly better desire and less distress than placebo. Researchers checked for chance, which didn't adequately explain the differences. Nausea, headaches, and skin that felt hot and looked red occurred most often among the side effects [3].
The next study enrolled 684 women for a further 52-week period [4]. Some left before the full year, but desire remained improved among those studied. Researchers found no newly appearing safety problems; sickness, headaches, and hot skin continued [4]. Everyone knew the shots contained medicine, and nobody received placebo, so hopes of feeling better could have influenced how the women answered questions about their sexual interest during treatment.
PT-141 benefits chiefly concern women's desire and distress
Studies found slightly stronger interest and less upset in women before menopause [3][4]. These PT-141 benefits continued during the year of further treatment. A study result doesn't promise that any woman will feel worthwhile relief. The results don't establish help for your erection difficulty either.
Earlier testing compared different shot amounts in women who had sexual difficulties [8]. The women's comparison shots contained placebo, an injection containing no active medicine. Phase 3, the larger testing before approval, used the amount selected from those results. Phase 3 results in those women still don't decide care for your own symptoms.
An earlier nose-spray test included 18 women who struggled to become sexually excited [7]. The women reported moderate or strong desire more often after a single spray containing 20 milligrams. Placebo brought less of that response, but this remained an early test. The findings from men give you a separate account of the uncertainties about erections.
Experts question whether the small gain feels worthwhile
During Phase 3, the larger studies before approval, women reported small improvements [3]. Desire rose slightly, and question 13 showed a little less distress. A later review of Phase 3 results doubted whether those gains made much difference day to day [9]. Your doctor can discuss that doubt without denying that the studies found a difference.
A real gain may still feel too small beside frequent nausea. Approval doesn't tell you whether the benefit will feel worth the trouble. In 2026, experts reviewed how doctors assess and treat women distressed because sexual interest had faded [15]. They discussed bremelanotide among approved treatment choices, rather than establishing large or certain benefit.
That review considered assessment as well as medicine for the symptoms. The discussion can't say how much relief any particular woman will feel. Ask your doctor whether the evidence fits your problem and your health. You can also ask what visits would involve, including the time and cost.
PT-141 for women is approved for one form of troubling loss of interest
The approved PT-141 for women use concerns troubling loss of previously normal desire [3][6]. The women still have monthly periods and haven't reached menopause. Their interest stays low with different partners and in different settings. Another illness or difficulty with a relationship can't better explain their symptoms [3].
PT-141, named bremelanotide on the label, is given as a shot when needed and affects desire inside the brain [6]. Flibanserin, another approved drug for this problem, is a daily pill with a different action. Ask your doctor about the practical differences between the medicines. The visit can include unwanted effects, treatment time, and cost.
Men, women after menopause, and erection treatment are outside the approval. Studies in those groups provide much less evidence about benefit. Early erections in men don't establish lasting relief from sexual difficulties. Your own symptoms and medical history need assessing before any treatment decision.
PT-141 approval doesn't predict a result for you
In Phase 3, the two RECONNECT studies found small benefits in women before menopause [3]. Phase 3 means the larger tests needed before approval. A later review questioned whether the gains were useful in ordinary life [9]. Other uses lack that level of testing, leaving your possible benefit uncertain.